Exacerbations and Real-World Outcomes Among Patients with Chronic Obstructive Pulmonary Disease Following Severe Exacerbation

Trial Identifier:	D5980R00121
Sponsor:	AstraZeneca
Start Date:	October 2025
Primary Completion Date:	November 2025
Study Completion Date:	November 2025
Condition:	Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
USA, Maryland	Gaithersburg, Maryland, USA, 20878

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.